SOURCE: Monaghan Medical Corporation

Monaghan Medical Corporation, Respiratory Devices

October 01, 2014 10:00 ET

Monaghan Medical Releases Robarts Research Institute Study Confirming Aerobika® OPEP Provides Drug-Free Relief for COPD Patients

PLATTSBURGH, NY--(Marketwired - October 01, 2014) - The Robarts Research Institute (Western University, London, ON) released a study demonstrating that, after 3 weeks of daily use, the Aerobika® device provides statistically significant outcomes in patients with Chronic Obstructive Pulmonary Disease (COPD) and Bronchiectasis. The study evaluated patients' on Pulmonary Function Test, Six Minute Walk Test, the St. George's Respiratory Questionnaire (SGRQ), the Patient Evaluation Questionnaire (PEQ) and Hyperpolarized Helium-3 Magnetic Resonance Lung Imaging (3He MRI). Patients' improvements included increased mucus clearance, decreased cough frequency and breathlessness, and enhanced exercise tolerance. Additionally, the study revealed that patients reported an overall improvement in quality of life, without any adverse events reported while using the device. 

In the United States, over 24 million people suffer from COPD, commonly exhibiting excessive mucus resulting in breathlessness as a primary symptom. When mucus is not cleared from the lungs, it can become a breeding ground for bacteria and infections, often leading to exacerbations, hospitalizations and even death. In 2010, the cost of COPD in the United States was projected to be $50 Billion, with hospitalization accounting for the majority of these costs.

In 2010, the Patient Protection and Affordable Care Act (PPACA) was approved by Congress. As part of the PPACA, the Medicare Readmissions Reduction Program (MRRP) was created, under which hospitals are penalized for "excess" readmissions for specific diagnoses. On Oct. 1st, 2014, COPD will be added as one of the conditions for which readmissions are monitored.

"The results from the Robarts study provide compelling evidence that patients suffering from COPD, Cystic Fibrosis (CF) or Bronchiectasis can now have an improved quality of life and a safe and easy-to-use method to address the unmet need of mucus clearance and potentially reduce the need for hospitalization," states Dominic Coppolo, Vice President of Clinical Affairs at Monaghan Medical Corporation.

The Aerobika® Oscillating Positive Expiratory Pressure (OPEP) device is a drug-free, easy to use, hand-held device with a proprietary pressure-oscillation dynamic that provides intermittent resistance and creates positive pressure and oscillations simultaneously, which mobilizes and assists mucociliary clearance to the upper airways where it can be coughed out. The Aerobika® is available at many leading hospitals across the United States. The Aerobika® OPEP device is marketed by Monaghan Medical Corporation in the United States. For an informational video and a copy of the Robarts study, please visit

Monaghan Medical Corporation
 (MMC), headquartered in Plattsburgh, New York (USA), is a leader in the development, manufacture and marketing of respiratory devices, from the flagship AeroChamber® Brand of Valved Holding Chamber (VHC) for asthma patients to the latest state-of-the-art Aerobika® OPEP therapy. Its best-in-class respiratory management products are developed and validated in its parent company's world-renowned Trudell Medical Aerosol Institute and are supported by over 500 peer reviewed articles published in various medical journals. 

Embedded Video Available:

Contact Information